Eric Baron

Eric Baron

Auto-generated profile, based on publicly available information

Eric Baron

Global Biometrics, Servier, Boston, MA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2024 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
WBWilliam L. Baker
William L. Baker
TMTimothy E. Moore
Timothy E. Moore
EBEric Baron
Eric Baron
MKMichelle Kittleson
Michelle Kittleson
WPWilliam F. Parker
William F. Parker
AJAbhishek Jaiswal
Abhishek Jaiswal

2 October 2023 in The American Statistician
Verified
Journal Article
Closed access
SPSachin S. Pandya
Sachin S. Pandya
XLXiaomeng Li
Xiaomeng Li
EBEric Barón
Eric Barón
TMTimothy E. Moore
Timothy E. Moore

1 August 2025 in JCO Precision Oncology
Verified
Journal Article
Open access
AKAlexander M. Kaizer
Alexander M. Kaizer
XZXiaojiang Zhan
Xiaojiang Zhan
EBEric Baron
Eric Baron
RTRui Sammi Tang
Rui Sammi Tang
DHDavid S. Hong
David S. Hong
BHBrian P. Hobbs
Brian P. Hobbs
PURPOSE: Master protocols represent transformations, enabling multiple therapies or diseases under a single protocol. These designs streamline therapeutic development by reducing redundancies. Suited for evolving fields such as oncology and global emergencies such as the COVID-19 pandemic, master protocols have been exemplified by studies such as RECOVERY, Solidarity, and I-SPY 2, which accelerated effective treatment identification (with I-SPY 2 focused on molecular subtypes). Recent oncology examples, such as MORPHEUS, evaluate immunotherapy combinations with shared controls. Despite advantages, their application in early-phase oncology remains underutilized amid growing regulatory emphasis on randomization for robust evidence. METHODS: US Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) initiatives, such as Project Optimus and Project FrontRunner, emphasize randomization in early-phase oncology trials. However, these initiatives pose challenges, including larger sample sizes, patient and physician reluctance to randomization, and high failure rates from poor accrual. To address these, this article adapts master protocol designs to consolidate early-phase trials for novel therapeutics sharing a common backbone therapy, integrating hybrid controls from published standard-of-care data to minimize randomization to the control arm. RESULTS: By consolidating trials under a shared standard-of-care control arm, the proposed master protocol design reduces total sample size by as much as 55% when compared with independent trials (with control arm sizes 2.4-2.9 times lower), lowers costs and duration, and enhances enrollment through reduced randomization to controls. Incorporating hybrid controls from prior studies and sharing information among arms with common background standard-of-care further improve efficiency, increasing power (reaching 90% overall) while controlling type I error rates acceptable levels. CONCLUSION: Master protocol designs with hybrid controls and Bayesian information sharing enable the efficient integration of randomization into early-phase oncology trials, enhancing efficiency, cost-effectiveness, and patient-centricity while aligning with FDA OCE initiatives.

26 May 2025 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
WBWilliam L. Baker
William L. Baker
TMTimothy E. Moore
Timothy E. Moore
EBEric Baron
Eric Baron
MKMichelle M. Kittleson
Michelle M. Kittleson
WPWilliam F. Parker
William F. Parker
AJAbhishek Jaiswal
Abhishek Jaiswal